[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]
- PMID: 16038141
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]
Abstract
The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus and increase of fat accumulation in adipocytes. The blockade of the cannabinoid system (CB1) by the specific inhibitor (rimonabant) decreases food intake and adiposity in animals and in humans. Moreover rimonabant lowers tobacco addiction. Clinical studies (RIO-LIPIDS and RIO-EUROPE) have recently confirmed that rimonabant combined with a hypocaloric diet over 1 year, promoted significant decrease of body weight, waist circumference and improvement of dyslipidemia. Rimonabant was well tolerated with mild and transient side effects. The future place of rimonabant in the strategy of obesity is still to be clarified.
Similar articles
-
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].J Pharm Belg. 2005;60(3):89-91. J Pharm Belg. 2005. PMID: 16252510 Review. French.
-
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258. Diabetes Care. 2008. PMID: 18227491
-
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.Lancet. 2005 Apr 16-22;365(9468):1389-97. doi: 10.1016/S0140-6736(05)66374-X. Lancet. 2005. PMID: 15836887 Clinical Trial.
-
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.J Clin Pharmacol. 2007 May;47(5):642-52. doi: 10.1177/0091270007299358. Epub 2007 Mar 28. J Clin Pharmacol. 2007. PMID: 17392496 Review.
-
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].Rev Med Liege. 2008 Jan;63(1):50-5. Rev Med Liege. 2008. PMID: 18303686 Review. French.
Cited by
-
Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide.Drug Metab Dispos. 2010 Nov;38(11):2075-82. doi: 10.1124/dmd.110.033712. Epub 2010 Aug 11. Drug Metab Dispos. 2010. PMID: 20702771 Free PMC article.